AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32350762 — intervention group
Group type: EXPERIMENTAL
Intervention: SSIDB with 2 ml of 1% lidocaine
Number of subjects: 90
Study 32350762 — intervention group
Group type: EXPERIMENTAL
Intervention: SSIDB with 1 ml of 1% lidocaine
Number of subjects: 90
Study 32350762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no digital block)
Number of subjects: 90
Study 32948055 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of ergometer cycling
Number of subjects: 18
Study 32948055 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lipid spectrum analysis
Number of subjects: 18
Study 32948055 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-hydroxyeicosatetranoic acid (HETE)
Number of subjects: 18
Study 33111575 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment Video‐feedback (PCA‐AVI)
Number of subjects: 69
Study 33111575 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational intervention (PCA‐PI)
Number of subjects: 69
Study 33111575 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA‐AVI
Number of subjects: 69
Study 33111575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCA groups
Number of subjects: 69
Study 33903656 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM intervention as an adjunct to usual care
Number of subjects: 101
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Oral Health Literacy (OHL) score
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable learning environment
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite skin color
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low satisfaction with the last dental appointment
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low OHL score (final model)
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite skin color (final model)
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (final model)
Number of subjects: 740
Study 33721863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low satisfaction with the last dental appointment (final model)
Number of subjects: 740
Study 32665381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral switch antibiotic therapy after initial intravenous therapy
Number of subjects: 324
Study 32665381 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy
Number of subjects: 324
Study 32665381 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 324
Study 34355232 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectables (LAI)
Number of subjects: 688
Study 34355232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antipsychotics (OAP)
Number of subjects: 688
Study 34355232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 688
Study 34355232 — intervention group
Group type: COMPARATOR
Intervention: Predictors of relapse
Number of subjects: 688
Study 34406341 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser trabeculotomy (FLT)
Number of subjects: 12
Study 34406341 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study 36087612 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence measured by tenofovir diphosphate concentrations of at least 700 fmol/punch
Number of subjects: 427
Study 36087612 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence measured by plasma tenofovir concentrations of at least 40 ng/mL
Number of subjects: 427
Study 36087612 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifiable concentrations of tenofovir diphosphate
Number of subjects: 427
Study 36087612 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantifiable concentrations of tenofovir
Number of subjects: 427
Study 35584248 — intervention group
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine 5 mL
Number of subjects: 78
Study 35584248 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 mL
Number of subjects: 78
Study 35584248 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 20 mL
Number of subjects: 78
Study 32805013 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Number of subjects: 226
Study 32805013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 226
Study 32805013 — intervention group
Group type: COMPARATOR
Intervention: Stress education
Number of subjects: 226
Study 32805013 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga vs CBT
Number of subjects: 226
Study 32004517 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMENCE
Number of subjects: 102
Study 32004517 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 102
Study 36437222 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 11
Study 36437222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 34617892 — intervention group
Group type: EXPERIMENTAL
Intervention: Half Somersault Maneuver (HSM)
Number of subjects: 43
Study 34617892 — intervention group
Group type: COMPARATOR
Intervention: Epley Maneuver (EM)
Number of subjects: 43
Study 34405362 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (50,000 IU in 100 ml normal saline)
Number of subjects: 30
Study 34405362 — intervention group
Group type: COMPARATOR
Intervention: 3% H2O2 (3% H2O2 in 100 ml normal saline in 1:10 dilution)
Number of subjects: 30
Study 34405362 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 30
Study 34405362 — intervention group
Group type: COMPARATOR
Intervention: 3% H2O2
Number of subjects: 30
Study 33686610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg single dose with 150 mg Mg2+
Number of subjects: 51
Study 33686610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg multiple doses with 75 mg Mg2+
Number of subjects: 51
Study 33686610 — intervention group
Group type: COMPARATOR
Intervention: Tramadol without Mg2+
Number of subjects: 51
Study 32084592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) plus standard care (systemic anticoagulation and/or antiplatelet therapy)
Number of subjects: 50
Study 32084592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) plus standard care
Number of subjects: 50
Study 32084592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 50
Study 32084592 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study 35120539 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered relational intervention
Number of subjects: 68
Study 34119535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 100 μg/ml
Number of subjects: 0
Study 34119535 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 400 μg/ml
Number of subjects: 0
Study 34119535 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept 100 μg/ml
Number of subjects: 0
Study 34119535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐MA or CQ (autophagy inhibitors)
Number of subjects: 0
Study 34119535 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia group (1% O2, 5% CO2, 94% N2)
Number of subjects: 0
Study 35382902 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBracelet with hand task practice
Number of subjects: 0
Study 35382902 — intervention group
Group type: COMPARATOR
Intervention: Control group (hand task practice alone)
Number of subjects: 0
Study 33496913 — intervention group
Group type: EXPERIMENTAL
Intervention: All implants
Number of subjects: 456
Study 33496913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis (143 patients)
Number of subjects: 456
Study 35410256 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music for 20 min in the pre‐ and postoperative period
Number of subjects: 0
Study 35410256 — intervention group
Group type: COMPARATOR
Intervention: Standard care in the pre‐ and postoperative period
Number of subjects: 0
Study 33652307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brightness Index (BI) from Landsat 8 images
Number of subjects: 180
Study 33652307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brightness Index (BI)
Number of subjects: 180
Study 33652307 — intervention group
Group type: EXPERIMENTAL
Intervention: USLE (Universal Soil Loss Equation) soil loss
Number of subjects: 180
Study 32521132 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran (2.5 mg/kg, subcutaneous, monthly for 6 months)
Number of subjects: 94
Study 32521132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 32521132 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran
Number of subjects: 94
Study 35175249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5145
Study 33859140 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 25
Study 33859140 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (control)
Number of subjects: 25
Study 34845313 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg of vitamin K2 (MK‐7)
Number of subjects: 60
Study 34845313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg of native vitamin D
Number of subjects: 60
Study 34845313 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg of vitamin K2 (MK‐7) and 10 µg of native vitamin D
Number of subjects: 60
Study 34845313 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 60
Study 34845313 — intervention group
Group type: COMPARATOR
Intervention: Healthy normal control
Number of subjects: 60
Study 34721612 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal crunch training protocol
Number of subjects: 40
Study 34721612 — intervention group
Group type: COMPARATOR
Intervention: Double straight leg raise (DSLR) exercise protocol
Number of subjects: 40
Study 33686887 — intervention group
Group type: EXPERIMENTAL
Intervention: SilvrSTAT Gel dressing
Number of subjects: 80
Study 33686887 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (wet-to-moist dressing with or without povidone-iodine)
Number of subjects: 80
Study 34491651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application of Zhanjin Huoxue formula combined with local cold compress (applied at specific acupoints, 4 hours each time, 2 times a day for 7 days)
Number of subjects: 62
Study 34491651 — intervention group
Group type: COMPARATOR
Intervention: Local cold compress (3 times a day for 7 days)
Number of subjects: 62
Study 34491651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application of Zhanjin Huoxue formula combined with local cold compress
Number of subjects: 62
Study 34491651 — intervention group
Group type: COMPARATOR
Intervention: Local cold compress
Number of subjects: 62
Study 32912951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological components delivered before pharmacological components (Group A)
Number of subjects: 0
Study 32912951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological components followed by non-pharmacological components (Group B)
Number of subjects: 0
Study 32912951 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 0
Study 35453051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental pollutants (biomarkers including lead, DDT, PCBs, PAHs, regulated phthalates, BPA)
Number of subjects: 428
Study 35453051 — intervention group
Group type: EXPERIMENTAL
Intervention: Household educational attainment and residential urbanicity as exposure determinants
Number of subjects: 428
Study 33442988 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifesaver VR training
Number of subjects: 352
Study 33442988 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face CPR training
Number of subjects: 352
Study 32326757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified relative dose response (MRDR) test
Number of subjects: 0
Study 32326757 — intervention group
Group type: COMPARATOR
Intervention: Serum retinol measurement
Number of subjects: 0
Study 33248910 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration nano-hydroxyapatite (nHAP) applied for 2 to 3 minutes daily for 10 days
Number of subjects: 60
Study 33248910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50μm aluminium oxide and 30 seconds etching after nHAP application
Number of subjects: 60
Study 33248910 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds etching after nHAP application
Number of subjects: 60
Study 33248910 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds etching after nHAP application
Number of subjects: 60
Study 33248910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nHAP application)
Number of subjects: 60
Study 32816944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg infusion with cisplatin and gemcitabine
Number of subjects: 0
Study 32816944 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 2.5 mg/kg infusion with cisplatin and gemcitabine
Number of subjects: 0
Study 32816944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 12.5 mg/day with cisplatin and gemcitabine
Number of subjects: 0
Study 32816944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day with cisplatin and gemcitabine
Number of subjects: 0
Study 32816944 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine chemotherapy without anti-VEGF therapy
Number of subjects: 0
Study 36012033 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG rehabilitation robot
Number of subjects: 0
Study 36012033 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 33672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling intervention (four cycling sessions; 1–2 h per session, one session per week)
Number of subjects: 360
Study 33672550 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 360
Study 33128006 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported walking pace
Number of subjects: 450967
Study 37142462 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid vaccination schedule (group R)
Number of subjects: 194
Study 37142462 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated conventional vaccination schedule (group A)
Number of subjects: 194
Study 37142462 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaccination schedule (group C)
Number of subjects: 194
Study 37142462 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (≥50 years old)
Number of subjects: 194
Study 37142462 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (≥60 years old)
Number of subjects: 194
Study 35090433 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted stress management-enhanced behavioral weight loss intervention (BWL-Stress)
Number of subjects: 340
Study 35090433 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight loss intervention alone (BWL-alone)
Number of subjects: 340
Study 35242594 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral therapy (CBT)
Number of subjects: 76
Study 35242594 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioral therapy (CBT)
Number of subjects: 76
Study 35157993 — intervention group
Group type: EXPERIMENTAL
Intervention: New NRG/RTOG contouring guidelines
Number of subjects: 300
Study 35157993 — intervention group
Group type: COMPARATOR
Intervention: Old RTOG/PARCER contouring guidelines
Number of subjects: 300
Study 35157993 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment after relapse
Number of subjects: 300
Study 35157993 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 300
Study 33606270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower TSH MoM
Number of subjects: 215
Study 33606270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower TSH
Number of subjects: 215
Study 33606270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational transient thyrotoxicosis
Number of subjects: 215
Study 33606270 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH and FT4
Number of subjects: 215
Study 35771652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid expansion (RME)
Number of subjects: 30
Study 35771652 — intervention group
Group type: COMPARATOR
Intervention: Slow expansion (SME)
Number of subjects: 30
Study 33838224 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus TPE (n=43)
Number of subjects: 87
Study 33838224 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=44)
Number of subjects: 87
Study 33596856 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy with transference work (N = 39)
Number of subjects: 69
Study 33596856 — intervention group
Group type: COMPARATOR
Intervention: Psychoanalytic psychotherapy without transference work (N = 31)
Number of subjects: 69
Study 32687161 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01B or RTS,S/AS01E (3 doses on a 0-1-7-month schedule, with the final 1 or 2 doses being fractional)
Number of subjects: 130
Study 32687161 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (2 doses: 1 full at month 0 and 1 fractional at month 7)
Number of subjects: 130
Study 32687161 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated participants)
Number of subjects: 130
Study 35166571 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy during pregnancy
Number of subjects: 50
Study 35166571 — intervention group
Group type: COMPARATOR
Intervention: Study arm (control group not specified)
Number of subjects: 50
Study 34491285 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time permitted group
Number of subjects: 125
Study 34491285 — intervention group
Group type: COMPARATOR
Intervention: Screen time abstinent group
Number of subjects: 125
Study 34491285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 125
Study 35560464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH) protocol with eight 4-minute hypoxic cycles at targeted arterial oxygen saturation of 80%
Number of subjects: 9
Study 35560464 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Normoxia (IN) protocol with eight 4-minute normoxic cycles
Number of subjects: 9
Study 35560464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia (IH)
Number of subjects: 9
Study 35560464 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Normoxia (IN)
Number of subjects: 9
Study 33851430 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Inventory of Malingered Symptomatology (SIMS)
Number of subjects: 82
Study 33851430 — intervention group
Group type: EXPERIMENTAL
Intervention: Miranda Quiz (MQ)
Number of subjects: 82
Study 33851430 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Clinical ILK (RC-ILK)
Number of subjects: 82
Study 33851430 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Legal Knowledge (ILK)
Number of subjects: 82
Study 34905143 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness skin grafting (FTSG)
Number of subjects: 52
Study 34905143 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh (SM)
Number of subjects: 52
Study 33149114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 130
Study 33149114 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CCVR)
Number of subjects: 130
Study 33149114 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable norethisterone enanthate (Net‐En)
Number of subjects: 130
Study 33149114 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 130
Study 33151132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron group (received routine care plus capsule of saffron 400 mg/day, 200 mg twice per day)
Number of subjects: 40
Study 33151132 — intervention group
Group type: COMPARATOR
Intervention: Control group (received routine stroke care)
Number of subjects: 40
Study 33151132 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron group
Number of subjects: 40
Study 33151132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 34259401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen acupuncture
Number of subjects: 60
Study 34259401 — intervention group
Group type: COMPARATOR
Intervention: Estazolam tablets (1 mg)
Number of subjects: 60
Study 32255785 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM in the sublingual region
Number of subjects: 14
Study 32255785 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM over the radial artery
Number of subjects: 14
Study 35237033 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg, s.c.)
Number of subjects: 40
Study 35237033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (s.c.)
Number of subjects: 40
Study 34677593 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone
Number of subjects: 111
Study 34677593 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone
Number of subjects: 111
Study 34677593 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 111
Study 34677593 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone vs placebo
Number of subjects: 111
Study 34677593 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone vs placebo
Number of subjects: 111
Study 34677593 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg methylprednisolone vs 40 mg methylprednisolone
Number of subjects: 111
Study 32789619 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous phrenic nerve stimulation (TPNS)
Number of subjects: 0
Study 32789619 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 32331064 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SPN-812
Number of subjects: 477